[8-K] Harvard Bioscience Inc Reports Material Event
Harvard Bioscience, Inc. announced a press release with financial results for the three and six months ended June 30, 2025, and scheduled a conference call at 8:00 AM ET on August 11, 2025. The Current Report (Form 8-K) states the press release is furnished as Exhibit 99.1 and that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except by specific reference in a future filing.
The report lists Exhibit 99.1 (press release) and Exhibit 104 (cover page interactive data) and is signed by Mark Frost, Interim Chief Financial Officer. No financial figures or performance metrics are provided within this 8-K; readers must consult Exhibit 99.1 for substantive results.
Harvard Bioscience, Inc. ha annunciato un comunicato stampa con i risultati finanziari per i tre e sei mesi terminati il 30 giugno 2025 e ha programmato una conference call alle 8:00 ET dell'11 agosto 2025. Il Current Report (Form 8-K) indica che il comunicato è fornito come Exhibit 99.1 e che tali informazioni non sono considerate "filed" ai fini della Sezione 18 dell'Exchange Act e non sono incorporate per riferimento, salvo che non vi sia un riferimento specifico in una futura dichiarazione.
Il rapporto elenca Exhibit 99.1 (comunicato stampa) e Exhibit 104 (dati interattivi della pagina di copertina) ed è firmato da Mark Frost, Chief Financial Officer ad interim. In questo 8-K non sono riportati dati finanziari o indicatori di performance; i lettori devono consultare l'Exhibit 99.1 per i risultati sostanziali.
Harvard Bioscience, Inc. anunció un comunicado de prensa con los resultados financieros correspondientes a los tres y seis meses terminados el 30 de junio de 2025 y programó una conferencia telefónica a las 8:00 AM ET del 11 de agosto de 2025. El Current Report (Form 8-K) indica que el comunicado se adjunta como Exhibit 99.1 y que la información no se considera "filed" a los efectos de la Sección 18 del Exchange Act y no se incorpora por referencia, salvo que se haga una referencia específica en una presentación futura.
El informe enumera Exhibit 99.1 (comunicado de prensa) y Exhibit 104 (datos interactivos de la portada) y está firmado por Mark Frost, Chief Financial Officer interino. Este 8-K no incluye cifras financieras ni métricas de rendimiento; los lectores deben consultar el Exhibit 99.1 para conocer los resultados sustantivos.
Harvard Bioscience, Inc.는 2025년 6월 30일로 종료되는 3개월 및 6개월 기간의 재무실적을 담은 보도자료를 발표하고, 2025년 8월 11일 오전 8:00(동부시간)에 컨퍼런스 콜을 예정했다고 밝혔습니다. Current Report (Form 8-K)에는 해당 보도자료가 Exhibit 99.1로 제출되었으며, 이 정보는 Exchange Act 섹션 18의 목적상 "filed"로 간주되지 않으며 향후 제출서에서 특정하게 참조되는 경우를 제외하고는 참조로 통합되지 않는다고 명시되어 있습니다.
보고서에는 Exhibit 99.1(보도자료) 및 Exhibit 104(표지 페이지 인터랙티브 데이터)가 기재되어 있으며, 임시 최고재무책임자인 Mark Frost가 서명했습니다. 이 8-K에는 재무 수치나 성과 지표가 포함되어 있지 않으므로 실질적 결과는 Exhibit 99.1을 확인해야 합니다.
Harvard Bioscience, Inc. a publié un communiqué de presse présentant les résultats financiers pour les trois et six mois clos le 30 juin 2025 et a prévu une conférence téléphonique le 11 août 2025 à 8h00 ET. Le Current Report (Form 8-K) précise que le communiqué est fourni en tant qu'Exhibit 99.1 et que ces informations ne sont pas considérées comme « filed » aux fins de la Section 18 de l'Exchange Act et ne sont pas incorporées par renvoi, sauf référence expresse dans un dépôt futur.
Le rapport énumère l'Exhibit 99.1 (communiqué de presse) et l'Exhibit 104 (données interactives de la page de couverture) et est signé par Mark Frost, Chief Financial Officer par intérim. Aucun chiffre financier ni indicateur de performance n'est inclus dans ce 8-K ; les lecteurs doivent consulter l'Exhibit 99.1 pour obtenir les résultats détaillés.
Harvard Bioscience, Inc. gab eine Pressemitteilung mit den Finanzergebnissen für die drei und sechs Monate zum 30. Juni 2025 bekannt und kündigte eine Telefonkonferenz für den 11. August 2025 um 8:00 Uhr ET an. Der Current Report (Form 8-K) führt aus, dass die Pressemitteilung als Exhibit 99.1 beigefügt wird und die Informationen für Zwecke von Section 18 des Exchange Act nicht als "filed" gelten und nicht durch Verweis aufgenommen werden, außer durch spezifische Bezugnahme in einer künftigen Einreichung.
Der Bericht führt Exhibit 99.1 (Pressemitteilung) und Exhibit 104 (interaktive Titelseitendaten) auf und ist von Mark Frost, Interim Chief Financial Officer, unterzeichnet. Dieser 8-K enthält keine finanziellen Zahlen oder Leistungskennzahlen; für die tatsächlichen Ergebnisse müssen Leser Exhibit 99.1 heranziehen.
- Company notified investors publicly of Q2 and six-month results and scheduled an investor conference call
- Press release furnished as Exhibit 99.1 with interactive data included as Exhibit 104
- No financial figures or performance metrics are included within this 8-K; substantive results are not present in the filing
- Disclosure is "furnished" and not "filed," limiting Section 18 liability and incorporation by reference, which reduces legal recourse tied to the 8-K itself
Insights
TL;DR: The company announced Q2/QTD results and an investor call, but the 8-K furnishes the press release without including financial figures.
The Form 8-K communicates that Harvard Bioscience issued a press release covering results for the three and six months ended June 30, 2025, and scheduled a conference call at 8:00 AM ET on August 11, 2025. Because the numbers are not included in this filing, the immediate material impact of this 8-K is limited; investors must review Exhibit 99.1 and attend or listen to the conference call to assess performance. The filing follows common disclosure practice of furnishing press releases and interactive data.
TL;DR: The 8-K furnishes a press release and clarifies legal status of the disclosure; signature by an interim CFO is noted.
The report explicitly states the press release is "furnished" rather than "filed," which limits Section 18 liability and prevents automatic incorporation by reference into future filings absent specific reference. The filing also identifies Mark Frost as Interim Chief Financial Officer signing the report. For governance and disclosure oversight, stakeholders should note the distinction between furnished and filed materials and refer to Exhibit 99.1 for the substantive information underlying this disclosure.
Harvard Bioscience, Inc. ha annunciato un comunicato stampa con i risultati finanziari per i tre e sei mesi terminati il 30 giugno 2025 e ha programmato una conference call alle 8:00 ET dell'11 agosto 2025. Il Current Report (Form 8-K) indica che il comunicato è fornito come Exhibit 99.1 e che tali informazioni non sono considerate "filed" ai fini della Sezione 18 dell'Exchange Act e non sono incorporate per riferimento, salvo che non vi sia un riferimento specifico in una futura dichiarazione.
Il rapporto elenca Exhibit 99.1 (comunicato stampa) e Exhibit 104 (dati interattivi della pagina di copertina) ed è firmato da Mark Frost, Chief Financial Officer ad interim. In questo 8-K non sono riportati dati finanziari o indicatori di performance; i lettori devono consultare l'Exhibit 99.1 per i risultati sostanziali.
Harvard Bioscience, Inc. anunció un comunicado de prensa con los resultados financieros correspondientes a los tres y seis meses terminados el 30 de junio de 2025 y programó una conferencia telefónica a las 8:00 AM ET del 11 de agosto de 2025. El Current Report (Form 8-K) indica que el comunicado se adjunta como Exhibit 99.1 y que la información no se considera "filed" a los efectos de la Sección 18 del Exchange Act y no se incorpora por referencia, salvo que se haga una referencia específica en una presentación futura.
El informe enumera Exhibit 99.1 (comunicado de prensa) y Exhibit 104 (datos interactivos de la portada) y está firmado por Mark Frost, Chief Financial Officer interino. Este 8-K no incluye cifras financieras ni métricas de rendimiento; los lectores deben consultar el Exhibit 99.1 para conocer los resultados sustantivos.
Harvard Bioscience, Inc.는 2025년 6월 30일로 종료되는 3개월 및 6개월 기간의 재무실적을 담은 보도자료를 발표하고, 2025년 8월 11일 오전 8:00(동부시간)에 컨퍼런스 콜을 예정했다고 밝혔습니다. Current Report (Form 8-K)에는 해당 보도자료가 Exhibit 99.1로 제출되었으며, 이 정보는 Exchange Act 섹션 18의 목적상 "filed"로 간주되지 않으며 향후 제출서에서 특정하게 참조되는 경우를 제외하고는 참조로 통합되지 않는다고 명시되어 있습니다.
보고서에는 Exhibit 99.1(보도자료) 및 Exhibit 104(표지 페이지 인터랙티브 데이터)가 기재되어 있으며, 임시 최고재무책임자인 Mark Frost가 서명했습니다. 이 8-K에는 재무 수치나 성과 지표가 포함되어 있지 않으므로 실질적 결과는 Exhibit 99.1을 확인해야 합니다.
Harvard Bioscience, Inc. a publié un communiqué de presse présentant les résultats financiers pour les trois et six mois clos le 30 juin 2025 et a prévu une conférence téléphonique le 11 août 2025 à 8h00 ET. Le Current Report (Form 8-K) précise que le communiqué est fourni en tant qu'Exhibit 99.1 et que ces informations ne sont pas considérées comme « filed » aux fins de la Section 18 de l'Exchange Act et ne sont pas incorporées par renvoi, sauf référence expresse dans un dépôt futur.
Le rapport énumère l'Exhibit 99.1 (communiqué de presse) et l'Exhibit 104 (données interactives de la page de couverture) et est signé par Mark Frost, Chief Financial Officer par intérim. Aucun chiffre financier ni indicateur de performance n'est inclus dans ce 8-K ; les lecteurs doivent consulter l'Exhibit 99.1 pour obtenir les résultats détaillés.
Harvard Bioscience, Inc. gab eine Pressemitteilung mit den Finanzergebnissen für die drei und sechs Monate zum 30. Juni 2025 bekannt und kündigte eine Telefonkonferenz für den 11. August 2025 um 8:00 Uhr ET an. Der Current Report (Form 8-K) führt aus, dass die Pressemitteilung als Exhibit 99.1 beigefügt wird und die Informationen für Zwecke von Section 18 des Exchange Act nicht als "filed" gelten und nicht durch Verweis aufgenommen werden, außer durch spezifische Bezugnahme in einer künftigen Einreichung.
Der Bericht führt Exhibit 99.1 (Pressemitteilung) und Exhibit 104 (interaktive Titelseitendaten) auf und ist von Mark Frost, Interim Chief Financial Officer, unterzeichnet. Dieser 8-K enthält keine finanziellen Zahlen oder Leistungskennzahlen; für die tatsächlichen Ergebnisse müssen Leser Exhibit 99.1 heranziehen.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 11, 2025, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and six months ended June 30, 2025, and the details of a related conference call to be held at 8:00 AM ET on August 11, 2025. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Press Release issued by Harvard Bioscience, Inc. on August 11, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HARVARD BIOSCIENCE, INC. | |||
| Date: August 11, 2025 | By: | /s/ Mark Frost | |
| Mark Frost | |||
| Interim Chief Financial Officer | |||
FAQ
When did Harvard Bioscience (HBIO) announce results for Q2 2025?
Which periods are covered by the announced results?
When is the investor conference call scheduled?
Where can I find the full press release referenced in the 8-K?
Is the information in the press release considered "filed" with the SEC?
